iBio (IBIO) EBT Margin (2011 - 2025)

iBio (IBIO) posted quarterly EBT Margin of 5720.0% for Q3 2025, down 136.46% quarter-over-quarter from 2419.0% in Q2 2025.

iBio (IBIO) EBT Margin (2011 - 2025) Analysis & Trends

iBio (IBIO) has reported EBT Margin for 15 consecutive years, with 5720.0% the latest figure, recorded in Q3 2025.

In Q3 2025, EBT Margin changed N/A year-over-year to 5720.0%; the TTM figure through Mar 2026 stood at 9166.67% (down 482267.0% YoY), while the FY2025 annual figure was 20389.25%, up 1122008.0% from the prior year.
EBT Margin retreated to 5720.0% in Q3 2025 per IBIO's latest filing, from 2419.0% in the prior quarter.
Across five years, EBT Margin topped out at 374.78% in Q1 2022 and bottomed at 44313.1% in Q3 2021.
Historically, EBT Margin has averaged 7768.44% across 5 years, with a median of 2224.0% in 2024.
On a YoY basis, EBT Margin climbed as much as 386913 bps in 2021 and fell as far as 4247553 bps in 2021.
iBio's EBT Margin stood at 44313.1% in 2021, then surged by 99 bps to 374.78% in 2022, then slumped by 2608 bps to 10148.0% in 2023, then surged by 78 bps to 2224.0% in 2024, then plunged by 157 bps to 5720.0% in 2025.
Business Quant data shows IBIO's EBT Margin at 5720.0% in Q3 2025, 2419.0% in Q2 2025, and 2224.0% in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	35.61%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	35.71%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	13.77%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-2.67%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-25.06%
10	iBio	175.21 Mn	175.21 Mn	-	-

Download Data